Inavolisib clinical trials
Also written GDC-0077, RO7113755 and Itovebi.
ClinicalTrials.gov finds 37 studies for inavolisib. How that becomes 32 here
Every study that search finds has been read, to see whether and how it gives inavolisib. ClinicalTrials.gov counts as of Nov 15, 2026. How drug pages count
- 37Found by its intervention search · See all 37 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 34 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −1
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139 · Tersolisib, a different PI3K-alpha inhibitorReport a problem
- 36Give inavolisib to participants
- −3Observe patients on it, or give it outside a trial
- −1Give it beside what is tested
- 32Test it: the count on this site
Get an email when these change. Save the inavolisib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 10 Oct 2024 · ITOVEBI · NDA 219249 (FDA, Drugs@FDA)
- European Union
- 18 Jul 2025 · Itovebi · EMEA/H/C/006353 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2026 (10)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 8 |
| 2023 | 6 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 10 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 20 · Other 12
Hoffmann-La Roche (17) · Genentech, Inc. (3) · German Cancer Research Center (2) · MedSIR (1) · Women's Hospital School Of Medicine Zhejiang University (1) · Fudan University (1) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) · National Cancer Institute, Naples (1)
Often tested with
Tested in the same studies.
Ipatasertib (8) · Atezolizumab (7) · Giredestrant (5) · Ado-Trastuzumab Emtansine (4) · Bevacizumab (4) · Tiragolumab (4) · Paclitaxel (3) · Alectinib (3)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 1 most studied
New when their studies opened, with inavolisib beside them; studies of each.
Reaching primary completion within a year · 8, 2 in phase 3
Studies that test inavolisib, phase 3 first.
- Nov 2026A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyPhase 3 · Hoffmann-La Roche
- May 2027A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerPhase 3 · Hoffmann-La Roche
- Dec 2026A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBCPhase 2 · Zhimin Shao
- Dec 2026To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerPhase 1 · Genentech, Inc.
- Jan 2027Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerPhase 2 · GBG Forschungs GmbH
- Jul 2027A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated CancersPhase 1 · Hoffmann-La Roche
- Jul 2027Oral GDC-0077 in Premature Ovarian InsufficiencyPhase 1 · Women's Hospital School Of Medicine Zhejiang University
- Jul 2027A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerPhase 2 · Hoffmann-La Roche
Studies
Open first, then newest update. How each study uses inavolisib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 32
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruitingPhase 3Hoffmann-La RocheNCT05894239Added to Phesgo maintenance in HER2-positive disease (INAVO122)Written as InavolisibReport a problem
- A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesRecruitingPhase 2Hoffmann-La RocheNCT07748208Safety with fulvestrant, with or without palbociclibWritten as InavolisibReport a problem
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingPhase 1Hoffmann-La RocheNCT04929223With cetuximab or bevacizumab in colorectal cancerWritten as InavolisibReport a problem
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingPhase 3Hoffmann-La RocheNCT05862285Continued for people from earlier Roche studiesWritten as InavolisibReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005With CDK4/6 inhibitors, endocrine drugs or trastuzumab deruxtecan in platform armsWritten as Inavolisib (Dose #1)Report a problem
- A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Hoffmann-La RocheNCT07287150With enzalutamide in castration-resistant prostate cancerWritten as InavolisibReport a problem
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerRecruitingPhase 3Hoffmann-La RocheNCT06790693Added to a CDK4/6 inhibitor and letrozole (INAVO123)Written as InavolisibReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Added to new giredestrant in one cohort (MORPHEUS)Written as InavolisibReport a problem
- To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07368998Two doses with fulvestrant after its approvalWritten as InavolisibReport a problem
- A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07405801Added to ribociclib and fulvestrantWritten as InavolisibReport a problem
- Oral GDC-0077 in Premature Ovarian InsufficiencyNot yet recruitingPhase 1Women's Hospital School Of Medicine Zhejiang UniversityNCT07904208In premature ovarian insufficiencyWritten as GDC-0077Report a problem
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyRecruitingPhase 3Hoffmann-La RocheNCT05646862Against alpelisib, both with fulvestrant (INAVO121)Written as InavolisibReport a problem
- A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07054190Neoadjuvant combinations in early breast cancerWritten as InavolisibReport a problem
- Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT05306041Added to neoadjuvant endocrine therapy and PhesgoWritten as InavolisibReport a problem
- A Multicenter, Single Arm Study to Evaluate the Preliminary Efficacy and Safety Profile of Inavolisib in Previously Treated Pancreatic Ductal Adenocarcinoma PatientsNot yet recruitingPhase 2Fudan UniversityNCT07694973Alone in previously treated pancreatic cancerWritten as InavolisibReport a problem
- A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07618390With ribociclib and fulvestrant, single armWritten as Inavolisib + Ribociclib + FulvestrantReport a problem
- Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4Not yet recruitingPhase 2National Cancer Institute, NaplesNCT07522697Alone in PIK3CA-mutated endometrial cancer (MITO END-4)Written as InavolisibReport a problem
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352In one endometrial cancer cohortWritten as InavolisibReport a problem
- A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA MutationNot yet recruitingPhase 2Hu HaiNCT07441512With eribulin in PIK3CA-mutated triple-negative breast cancerWritten as Inavolisib in Combination With EribulinReport a problem
- A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBCNot yet recruitingPhase 2Zhimin ShaoNCT07245797Added to neoadjuvant Phesgo and nab-paclitaxelReport a problem
See all 32 studies that test inavolisib →
Behind its US label · 1 — the studies the FDA label of ITOVEBI describes
From the Clinical Studies section of ITOVEBI (2026-04), as openFDA has it. A study the site does not hold is left out.
- A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerActive, not recruitingPhase 2/3Hoffmann-La RocheNCT04191499Report a problem
Tested on its own · 4 — no other medicine in its arm
- Oral GDC-0077 in Premature Ovarian InsufficiencyNot yet recruitingPhase 1Women's Hospital School Of Medicine Zhejiang UniversityNCT07904208In premature ovarian insufficiencyWritten as GDC-0077Report a problem
- A Multicenter, Single Arm Study to Evaluate the Preliminary Efficacy and Safety Profile of Inavolisib in Previously Treated Pancreatic Ductal Adenocarcinoma PatientsNot yet recruitingPhase 2Fudan UniversityNCT07694973Alone in previously treated pancreatic cancerWritten as InavolisibReport a problem
- Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4Not yet recruitingPhase 2National Cancer Institute, NaplesNCT07522697Alone in PIK3CA-mutated endometrial cancer (MITO END-4)Written as InavolisibReport a problem
- A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of InavolisibCompletedPhase 1Genentech, Inc.NCT07144111Single dose across liver impairmentWritten as InavolisibReport a problem
Tested with established drugs · 12 — they are given beside it
- A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast CancerRecruitingPhase 3Hoffmann-La RocheNCT05894239Added to Phesgo maintenance in HER2-positive disease (INAVO122)Written as InavolisibReport a problem
- A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesRecruitingPhase 2Hoffmann-La RocheNCT07748208Safety with fulvestrant, with or without palbociclibWritten as InavolisibReport a problem
- A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingPhase 2Hoffmann-La RocheNCT07287150With enzalutamide in castration-resistant prostate cancerWritten as InavolisibReport a problem
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast CancerRecruitingPhase 3Hoffmann-La RocheNCT06790693Added to a CDK4/6 inhibitor and letrozole (INAVO123)Written as InavolisibReport a problem
- To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07368998Two doses with fulvestrant after its approvalWritten as InavolisibReport a problem
- A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07405801Added to ribociclib and fulvestrantWritten as InavolisibReport a problem
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyRecruitingPhase 3Hoffmann-La RocheNCT05646862Against alpelisib, both with fulvestrant (INAVO121)Written as InavolisibReport a problem
- Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT05306041Added to neoadjuvant endocrine therapy and PhesgoWritten as InavolisibReport a problem
- A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated CancersActive, not recruitingPhase 1Hoffmann-La RocheNCT06496568Alone or with atezolizumab in PIK3CA-mutated cancersWritten as InavolisibReport a problem
- A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerActive, not recruitingPhase 2/3Hoffmann-La RocheNCT04191499On the US labelAdded to palbociclib and fulvestrant (INAVO120)Written as InavolisibReport a problem
- To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast CancerActive, not recruitingPhase 1Genentech, Inc.NCT03006172First-in-human, alone or with endocrine and HER2 partnersWritten as InavolisibReport a problem
- A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal CancerWithdrawnPhase 2Hoffmann-La RocheNCT07323576Added to bevacizumab and chemotherapy in colorectal cancerWritten as InavolisibReport a problem
Tested in a combination · 16 — another drug in the study is under test too
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingPhase 1Hoffmann-La RocheNCT04929223With cetuximab or bevacizumab in colorectal cancerWritten as InavolisibReport a problem
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingPhase 3Hoffmann-La RocheNCT05862285Continued for people from earlier Roche studiesWritten as InavolisibReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005With CDK4/6 inhibitors, endocrine drugs or trastuzumab deruxtecan in platform armsWritten as Inavolisib (Dose #1)Report a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Added to new giredestrant in one cohort (MORPHEUS)Written as InavolisibReport a problem
- A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07054190Neoadjuvant combinations in early breast cancerWritten as InavolisibReport a problem
- A Phase ll, Interventional, Single-arm Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib and Fulvestrant in Chinese Patients With PIK3CA-mutant, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer.Not yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07618390With ribociclib and fulvestrant, single armWritten as Inavolisib + Ribociclib + FulvestrantReport a problem
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingPhase 1/2Alliance Foundation Trials, LLC.NCT04486352In one endometrial cancer cohortWritten as InavolisibReport a problem
- A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA MutationNot yet recruitingPhase 2Hu HaiNCT07441512With eribulin in PIK3CA-mutated triple-negative breast cancerWritten as Inavolisib in Combination With EribulinReport a problem
- A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBCNot yet recruitingPhase 2Zhimin ShaoNCT07245797Added to neoadjuvant Phesgo and nab-paclitaxelReport a problem
- Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingPhase 2German Cancer Research CenterNCT05332561One matched option after neoadjuvant therapyWritten as InavolisibReport a problem
- A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC PopulationActive, not recruitingPhase 2MedSIRNCT05708235Added to giredestrant on ctDNA relapse in one armWritten as InavolisibReport a problem
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingPhase 2Hoffmann-La RocheNCT04931342In two biomarker-driven arms in rare ovarian cancersWritten as InavolisibReport a problem
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845Alone in one tumour-agnostic cohortWritten as InavolisibReport a problem
- Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast CancerTerminatedPhase 2Bryan Schneider, MDNCT04849364For ctDNA-positive PIK3CA-altered residual triple-negative diseaseWritten as InavolisibReport a problem
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedPhase 2Genentech, Inc.NCT04632992Alone in one tumour-agnostic armWritten as InavolisibReport a problem
- CRAFT: The NCT-PMO-1602 Phase II TrialCompletedPhase 2German Cancer Research CenterNCT04551521One matched drug in sequencing-guided therapyWritten as InavolisibReport a problem
Beside a new treatment under test · 1 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with inavolisib: divarasib 1
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationActive, not recruitingPhase 1Genentech, Inc.NCT04449874Partner of new divarasib in one armWritten as InavolisibReport a problem
Observed · 3 — patients on it are followed, or it is given outside a trial
- A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerRecruitingHoffmann-La RocheNCT07347600Real-world use in endocrine-resistant breast cancer, observedWritten as InavolisibReport a problem
- Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient AdherenceRecruitingTianjin Medical University Cancer Institute and HospitalNCT07817056Its hyperglycaemia managed by risk, observedReport a problem
- A Real-World Study of Inavolisib in Patients With HR-Positive/HER2-Negative, PIK3CA-Mutated Advanced Breast CancerNot yet recruitingxuliangNCT07543250Real-world use with endocrine therapy, observedWritten as Inavolisib in Combination With ETReport a problem
What changed recently
From the registry's own updates since Oct 17, 2026.
Started recruiting1
Newly registered1
- Oral GDC-0077 in Premature Ovarian InsufficiencyOct 29, 2026NCT07904208
Codes
What other systems call inavolisib · ClinicalTrials.gg INT001966
- MeSH (NLM) C000723546inavolisibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) L4C1UY2NYHINAVOLISIBConfirmed FDA, NLM, Wikidata
- Wikidata Q76855355inavolisibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C132166InavolisibOne source FDA
- DrugBank DB15275One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723546 | inavolisib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | L4C1UY2NYH | INAVOLISIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q76855355 | inavolisib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C132166 | Inavolisib | One source FDA |
| DrugBank | DB15275 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.